Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TXG | CLUSTER | neutral | 2/10 | Two insiders at 10x Genomics, including the CFO, sold a combined $652K in open-market sales on May 22, 2026, at ~$24.44/ | May 27, 2026 |
| EDIT | 424B5 | bearish | 7/10 | Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M underwritten public of | May 26, 2026 |
| EDIT | 8-K | bearish | 7/10 | Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock and accompanying war | May 26, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Six TWST insiders—including the CEO, CFO, and COO—collectively sold 16,796 shares for ~$807K on May 21, 2026, all at $53 | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 8/10 | Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~ | May 26, 2026 |
| EDIT | 8-K | bullish | 5/10 | Editas Medicine suspended and terminated the prospectus supplement under its at-the-market (ATM) offering agreement with | May 26, 2026 |
| EDIT | 424B5 | bearish | 7/10 | Editas Medicine is conducting a dilutive underwritten public offering of common stock (and/or pre-funded warrants in lie | May 26, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warr | May 26, 2026 |
| EDIT | PRESS-RELEASE | bullish | 7/10 | Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean re | May 26, 2026 |
| PACB | DEFA14A | neutral | 3/10 | Pacific Biosciences of California, Inc. (PACB) filed additional definitive proxy soliciting materials (DEFA14A) on May 2 | May 22, 2026 |
| NEO | 8-K | neutral | 2/10 | NeoGenomics held its 2026 annual meeting on May 21, 2026, with 89.61% of outstanding shares represented. Stockholders ap | May 22, 2026 |
| ILMN | CLUSTER | neutral | 4/10 | Director Keith Meister sold 171,932 shares for $24.96M in open-market sales, while SVP Jakob Wedel Christensen sold 700 | May 14, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine reported new preclinical data for EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, | May 14, 2026 |
| EDIT | PRESS-RELEASE | bullish | 5/10 | Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction in NHPs durable thro | May 14, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in | May 13, 2026 |
| BEAM | PRESS-RELEASE | bullish | 7/10 | Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog | May 12, 2026 |
| FATE | PRESS-RELEASE | bullish | 7/10 | Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell pr | May 11, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3M loss in Q1 2025, w | May 11, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | Two directors sold a total of $240K in open-market stock following the Q1 earnings release, but this represents only 0.0 | May 8, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals reported Q1 2026 EPS of -$0.21, beating consensus of -$0.26 by 18.3%, while revenue of $6.5M m | May 6, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8 | May 5, 2026 |
| EDIT | 8-K | neutral | 4/10 | Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92 loss in Q1 2025, dr | May 5, 2026 |
| CRSP | 8-K | bearish | 5/10 | CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total revenue of $1.5M was up | May 4, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, w | May 4, 2026 |
| NEO | 8-K | bullish | 6/10 | NeoGenomics reported Q1 2026 revenue of $187M (+11% YoY), beating consensus of $184.5M, and raised full-year revenue gui | Apr 28, 2026 |
| EDIT | DEFA14A | neutral | 2/10 | Editas Medicine filed definitive additional proxy materials (DEFA14A) with no substantive new information disclosed. The | Apr 28, 2026 |
| NTLA | PRESS-RELEASE | bearish | 6/10 | Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, with an underwriter opt | Apr 27, 2026 |
| NTLA | 8-K | bullish | 8/10 | Intellia Therapeutics announced positive Phase 3 topline data for its investigational CRISPR-based therapy lonvo-z in he | Apr 27, 2026 |
| TXG | DEFA14A | neutral | 3/10 | Analysis based on filing metadata only — document content was unavailable | Apr 24, 2026 |
| FATE | DEFA14A | neutral | 3/10 | FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election | Apr 24, 2026 |